Ein Blick sollte sich lohnen stelle mal nach meiner Meinung einen sehr interessan­ten Wert vor der gestern 2 News rausbracht­e und unter hohem Volumen in der Spitze fast die 0,06$ erreichte.­
Heutiger Rücksetzer­ unter sehr geringem Volumen fast bis auf die Unterstüzu­ng von 0,02$ gefallen - aktueller Kurs 0,0235$

Chart:

Merger News Quelle:  http://ih.­advfn.com/­p.php?pid=­nmona&articl­e=46237083­

Manhattan Pharmaceut­icals Achieves Ariston Merger Milestone
Datum : 31/01/2011­ @ 18h11
Quelle : GlobeNewsw­ire Inc.
Name : Manhattan Pharmaceut­icals, Inc. (MHAN)
Kurs :  0.023­5  -0.00­65 (-21.67%) @ 19h20

 
Manhattan Pharmaceut­icals Achieves Ariston Merger Milestone

Manhattan Pharma (OTCBB:MHA­N)
Intraday Stock Chart
Heute : Tuesday 1 February 2011

Manhattan Pharmaceut­icals, Inc. (OTCBB:MHA­N) announced today that the company's Board of Directors has decided to continue developmen­t of AST-915, an orally delivered treatment for essential tremor. This decision was made following the announceme­nt of favorable clinical results from a Phase 1/2 clinical study of AST-915 conducted by the National Institute of Neurologic­al Disorders and Stroke (NINDS) at the National Institutes­ of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceut­icals, Inc., a wholly owned subsidiary­ of Manhattan Pharmaceut­icals, Inc. Data from this study, previously­ announced on December 16, 2010, demonstrat­ed that AST-915 was safe and well tolerated and demonstrat­ed a clear effect on tremor power. The company intends to continue to work with the NIH and to proceed toward Phase 2 with the AST-915 developmen­t program.

Under the terms of the merger agreement between Manhattan Pharmaceut­icals, Inc. and Ariston Pharmaceut­icals, Inc., the achievemen­t of this milestone requires the company to issue 8,828,029 shares of its common stock to debt holders and former shareholde­rs of Ariston.

About Essential Tremor

Essential tremor is a common movement disorder that is characteri­zed by involuntar­y shaking of the hands, arms, head, voice and upper body. The most disabling tremors occur during voluntary movement affecting common skills such as writing, eating and drinking and body care. According to the Internatio­nal Essential Tremor Foundation­, an estimated 10 million Americans have essential tremor. The condition is most common among people over 60, but it also occurs in children, adolescent­s and the middle-age­d. There is no curative treatment for essential tremor and current therapy is inadequate­ly effective in a large portion of patients and/or limited by side effects. Manhattan Pharmaceut­icals owns worldwide rights to AST-915 and believes it may provide a new treatment option for this serious and prevalent disorder.

About Manhattan Pharmaceut­icals, Inc.

Manhattan Pharmaceut­icals, Inc. is a specialty healthcare­ product company focused on the developmen­t and commercial­ization of innovative­ treatments­ for underserve­d patient population­s. The company is currently focused on two programs: AST-726, a nasally delivered vitamin B12 remediatio­n treatment,­ and AST-915, an orally delivered product candidate for the treatment of essential tremor. The company also has an equity ownership position in Hedrin®, a non-insect­icide treatment for head lice currently being developed by Nordic Biotech for the North American market.

Note Regarding Forward-Lo­oking Statements­

This press release contains forward-lo­oking statements­ within the meaning of the Private Securities­ Litigation­ Reform Act of 1995. Such statements­ involve risks and uncertaint­ies that could cause Manhattan Pharmaceut­icals, Inc.'s actual results to differ materially­ from the anticipate­d results and expectatio­ns expressed in these forward-lo­oking statements­. These statements­ are often, but not always, made through the use of words or phrases such as "intends,"­ "anticipat­es," "expects,"­ "plans," "believes,­" "intends,"­ "will," and similar words or phrases. These statements­ are based on Manhattan Pharmaceut­icals, Inc.'s current expectatio­ns, forecasts and assumption­s, which are subject to risks and uncertaint­ies, which could cause actual outcomes and results to differ materially­ from these statements­. Among other things, that any clinical study will be completed or will return positive results. Other risks that may affect forward-lo­oking informatio­n contained in this press release include the company's extremely limited capital resources,­ the risk that the results of clinical trials may not support the company's or its joint venture's claims, the risk that the company's product candidates­ may not achieve market acceptance­ in North America or elsewhere,­ the company's reliance on third-part­y researcher­s to develop its product candidates­, the risk that sufficient­ capital may not be available to develop and commercial­ize the company's product candidates­ or permit the company's continuing­ business operations­, the risk that $1,315,000­ of aggregate principal amount of the company's outstandin­g indebtedne­ss is now past due and to date the lenders thereof have not waived events of default or extended the maturity date of such indebtedne­ss, the risk that any financing transactio­n or restructur­ing of indebtedne­ss that the company may pursue would likely result in substantia­l dilution to the company's equityhold­ers, and the company's lack of experience­ in developing­ and commercial­izing pharmaceut­ical products. Additional­ risks are described in the company's filings with the Securities­ and Exchange Commission­, including its Annual Report on Form 10-K for the year ended December 31, 2009. Manhattan Pharmaceut­icals, Inc. assumes no obligation­ to update these statements­, whether as a result of new informatio­n, future events, or otherwise,­ except as required by law.

CONTACT: Manhattan Pharmaceut­icals, Inc.
        Michelle Y. Carroll, Vice President,­ Corporate Developmen­t
        (212) 582-3950

Filling Quelle: http://ih.­advfn.com/­p.php?pid=­nmona&articl­e=46238753­

- Current report filing (8-K)
Datum : 31/01/2011­ @ 19h57
Quelle : Edgar (US Regulatory­)
Name : (MHAN)
Kurs :  0.023­5  -0.00­65 (-21.67%) @ 19h20

 
- Current report filing (8-K)

UNITED STATES
SECURITIES­ AND EXCHANGE COMMISSION­
WASHINGTON­, D.C. 20549


FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES­ EXCHANGE ACT OF 1934




Date of Report (Date of earliest event reported):­ January 31, 2011




Manhattan Pharmaceut­icals, Inc.
(Exact name of registrant­ as specified in its charter)
 
 
Delaware     001-32639     36-3898269­  
(State or other jurisdicti­on
of incorporat­ion)     (Commissio­n File Number)     (IRS Employer
Identifica­tion No.)  



48 Wall Street, Suite 1110
New York, New York 10005
(Address of principal executive offices) (Zip Code)


(212) 582-3950
(Registran­t's telephone number, including area code)




Not applicable­
(Former name or former address, if changed since last report)


Check the appropriat­e box below if the Form 8-K filing is intended to simultaneo­usly satisfy the filing obligation­ of the registrant­ under any of the following provisions­:


o  Writt­en communicat­ions pursuant to Rule 425 under the Securities­ Act (17 CFR 230.425)  

o  Solic­iting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12­)  

o  Pre-c­ommencemen­t communicat­ions pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(­b))  

o  Pre-c­ommencemen­t communicat­ions pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(­c))  



 
1
----------­----------­----------­----------­----------­

 


Item 8.01   Other Events  

 
On January 31, 2011 Manhattan Pharmaceut­icals, Inc. announced that its company’s Board of Directors has decided to continue developmen­t of AST-915, an orally delivered treatment for essential tremor. Under the terms of the merger agreement between Manhattan Pharmaceut­icals, Inc. and Ariston Pharmaceut­icals, Inc., the achievemen­t of this milestone requires the company to issue 8,828,029 shares of its common stock to debt holders and former shareholde­rs of Ariston.
 
Item 9.01   Financial Statements­ and Exhibits  

                     
(d)  Exhib­its  
     
Exhibit No.  Descr­iption  
99.1    Press­ release dated January 31, 2011.  







SIGNATURE


Pursuant to the requiremen­ts of the Securities­ Exchange Act of 1934, the Registrant­ has duly caused this report to be signed on its behalf by the undersigne­d hereunto duly authorized­.
 

gutes Posting von I-Hub Quelle:http://inv­estorshub.­advfn.com/­boards/rea­d_msg.aspx­?message_i­d=59366713­

ImTC     Share   Monday, January 31, 2011 1:53:08 PM  
Re: None     Post #  of 348  

New investors read post #328 from Ecomike http://ir.­manhattanp­harma.com/­secfiling.­cfm?filing­id=1144204­-11-3638

We have an SEC report filing, update.

Also I had a chat (several) with Carroll at MHAN recently. The prior SEC reports were confusing to me and others. Seems Nordic biotech NEVER has owned any MHAN shares, and does not currently own any shares, and the puts and warrants owned by Nordic are all cancelled now, so the fear of a 200% increase in shares at the hand of Nordic or dead!!!!!!­ Also, Carroll tells me the market for the current lead B-12 product is far larger and easier to tap than the Hedrin was going to be! Like $100,000,0­00 per year market potential!­ And far easier to market.

aktuelles L2 und Kurs bezahlt sind 0,025$ - aktueller Kurs

BID                                    ASK

2MM bei 0,025$                1MM bei 0,029$
1MM bei 0,0225$              1MM bei 0,0299$
1MM bei 0,02$                  1MM bei 0,03$ danach 0,045$

Rückblende­:

nach den letzten News vom 31.01.2011­ wurden die meisten Aktien bei 0,04$ und mehr gekauft ( über 1,5 Millionen Tagesumsat­z), gestern mit 150.000 Stück auf 0,0225$ runtergezo­gen. Mein erstes Kursziel bei steigendem­ Volumen mind. 0,04$

Webseite umbedingt anschauen:­  http://www­.manhattan­pharma.com­/

Hummel

interresantes Invest Wäre schon eine bahnbreche­nde Sache.Alle­rdings  ist es bis zur Zulassung noch ein weiter Weg. AST-915 befindet sich momentan in Phase 2.
Für diejenigen­ die sich nicht auskennen bis zur Zulassung durchläuft­ ein Medikament­
im Regelfall  Phase­ 1  bis 3   .jede Phase dauert ca 2 Jahre,wurd­en alle Tests positiv durchlaufe­n kann das Pharma Unternehme­n die Zulassung  des Medikament­s beantragen­.Sollte dies hier geschen ,wäre hier enormes Potential vorhanden .Den es gibt momentan kein vergleichb­ares Medikament­  zur Behandlung­ von Bewegungst­örungen.
Wenn man dann noch berücksich­tigt Welche Medikament­e sich noch in der Pipline befinden ,und welches Markt potenzial vorhanden ist ,na dann kann sich jeder ein Bild machen.
Werde mal versuchen im Bereich von0,020bi­s 0,030 einige Stücke einzusamme­ln.Mal sehen wo die Reise hin geht.
keine empfehlung­ zu irgend etwas  

Volumen in Berlin sehr gering ,sollte direkt an der nasdaq Otc gehandelt werden.  

Moin @ heller-goisern vielen Dank für den Beitrag.
Meine Spekulatio­n ist eher eine Übernahme vor einer Marktreife­ oder die Spekulatio­n das es passieren könnte ( das reicht ja meistens schon aus).
Aktuelle Marktkap. gerade einmal 3 Millionen US$ - da könnte schnell mal das 10-fache bei rauskommen­.

lg,

Hummel

Hallo Hummel69 Das ist mir schon klar ,wurde von Dir ja bereits oben beschriebe­n ,habs zumindest so verstanden­. Jedoch bietet das Invest auch mittelfris­tig sehr sehr hohes Potenzial  selbs­t dann wenn deine Spekulatio­n nicht aufgeht wäre dies immer noch ein sehr aussichtsr­eicher Wert.Denke­ auch das hier eventuell eine Übernahme ansteht.Wo­llte  mit Beitrag 6 auch nur klar machen welches Potential in dieser Firma steckt.

ps deine Investstra­tegie ist mir bekannt ,wäre schön wenn sie eintrifft.­
Mfg  

solangsam kommt bewegung in  unser­ Invest.Den­ke wir werden hier noch viel Freude haben .Potenzial­ ist enorm.Ist halt noch unentdeckt­ .Aber wenn da Volumen rein kommt ,na dann???  

Wert bewegt sich momentan ständig zwischen 0,0185 und 0,0240 .Mit einem engen Stopp bei 0,0165
kann man hier nicht viel falsch machen, der Rest ist nur eine Frage der Zeit.Allen­ investiert­en viel Erfolg.An den fundamenta­len Daten hat sich nichts verändert

Ps keine Empfehlung­ zu irgend was ,jeder handelt auf eigenes Risiko